Zymeworks (ZYME) Accumulated Depreciation & Amortization (2021 - 2025)
Zymeworks recorded quarterly Accumulated Depreciation & Amortization of $7.7 million in Q4 2025, down 11.04% quarter-over-quarter from $8.7 million in Q4 2024, and down 11.04% year-over-year from $8.7 million in Q4 2024.
Zymeworks' Accumulated Depreciation & Amortization history runs 5 years deep, the most recent figure standing at $7.7 million for Q4 2025.
- In Q4 2025, Accumulated Depreciation & Amortization fell 11.04% year-over-year to $7.7 million; the TTM figure through Dec 2025 stood at $7.7 million (down 11.04% YoY), while the FY2025 annual figure was $7.7 million, down 11.04% from the prior year.
- Accumulated Depreciation & Amortization came in at $7.7 million for Q4 2025 at Zymeworks, down from $8.7 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $14.1 million in Q4 2021 to a low of $7.2 million in Q4 2022.
- A 5-year average of $9.6 million and a median of $8.7 million in 2024 frame the typical range for Accumulated Depreciation & Amortization.
- Across the five-year window, Accumulated Depreciation & Amortization slumped 48.55% in 2022 and surged 40.48% in 2023, its largest moves.
- Zymeworks' Accumulated Depreciation & Amortization stood at $14.1 million in 2021, then sank by 48.55% to $7.2 million in 2022, then soared by 40.48% to $10.2 million in 2023, then fell by 14.56% to $8.7 million in 2024, then dropped by 11.04% to $7.7 million in 2025.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $7.7 million, $8.7 million, and $10.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.73 Mn |
| Dec 31, 2025 | 7.73 Mn |
| Dec 31, 2024 | 8.68 Mn |
| Dec 31, 2024 | 8.68 Mn |
| Dec 31, 2023 | 10.16 Mn |
| Dec 31, 2023 | 10.16 Mn |
| Dec 31, 2022 | 7.24 Mn |
| Dec 31, 2022 | 7.24 Mn |
| Dec 31, 2021 | 14.06 Mn |
| Dec 31, 2021 | 14.06 Mn |